Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan

BMC Gastroenterology

Table 1 Clinical and laboratory data of patients with hematological malignancy

		Total	AML	ALL	Lymphoma	CML/MPN	CLL	MM	MDS/AA	p
Number		1962	606	160	769	60	27	197	143
Gender	Man	1048	326	83	399	36	16	108	81	0.799
Gender	Woman	914	280	77	370	24	11	89	62
Age, median(range), year		55(15–97)	54(17–92)	38(16–86)	57(15–97)	48(18–86)	61(37–89)	59(30–87)	55(17–94)	<0.001
HBs Ag(+) at diagnosis		286	75	13	142	6	5	31	14	0.002
HBV reactivation		97	29	3	46	1	2	10	6	0.335
HBs Ag(−) positive seroconversion		41	5	7	24	0	1	3	1	0.013
Hepatitis C		73	17	0	42	1	1	5	7	0.013
Liver cirrhosis		21	6	1	10	1	0	1	2	0.924
Hepatocellular carcinoma		9	3	0	4	2	0	0	0	0.038
Underlying diabetes		273	75	22	109	8	4	31	24	0.833
Allogeneic transplantation		439	233	81	48	18	2	3	54	<0.001

AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML/MPN chronic myeloid leukemia/myeloproliferative neoplasm, CLL chronic lymphocytic leukemia, MM myeloma, MDS/AA myelodysplastic syndrome/aplastic anemia

ISSN: 1471-230X